Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Mengyao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2082-0885; OpenAlex author ID A5080012876. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Multi-omics analyses inform mechanisms of immunotherapy response in pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1673098↗
  2. Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. First author DOI 10.1038/s41598-021-84394-4↗
  3. Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis. Co-author DOI 10.3892/ol.2019.10444↗
  4. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Co-author DOI 10.1080/15384101.2015.1127468↗
  5. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Co-author DOI 10.18632/oncotarget.9975↗
  6. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. First author DOI 10.1038/srep11836↗
  7. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradat… Co-author DOI 10.3892/or.2014.3266↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kai Chen · 4 shared papers, 2016–2025 · strength 0.48
  2. Mengdan Xu · 2 shared papers, 2019–2025 · strength 0.35
  3. Min Tao · 5 shared papers, 2014–2021 · strength 0.32
  4. Qiaoming Zhi · 4 shared papers, 2015–2021 · strength 0.28
  5. Meng Shen · 4 shared papers, 2015–2021 · strength 0.28
  6. Daoming Li · 3 shared papers, 2015–2021 · strength 0.28
  7. Jinming Cao · 1 shared paper, 2025 · strength 0.25
  8. Dapeng Li · 1 shared paper, 2025 · strength 0.25
  9. Yecheng Li · 1 shared paper, 2025 · strength 0.25
  10. Ge Li · 1 shared paper, 2025 · strength 0.25
  11. Wei Li · 2 shared papers, 2016–2021 · strength 0.18
  12. Wei Li · 1 shared paper, 2019 · strength 0.10
  13. Yihang Yuan · 1 shared paper, 2019 · strength 0.10
  14. Jian Zhou · 1 shared paper, 2019 · strength 0.10
  15. Wei Li · 2 shared papers, 2014–2015 · strength 0.09
  16. Wei Li · 1 shared paper, 2016 · strength 0.05
  17. Lu Liu · 1 shared paper, 2016 · strength 0.05
  18. Lian Lian · 1 shared paper, 2016 · strength 0.05
  19. Weiming Duan · 1 shared paper, 2016 · strength 0.05
  20. Zekuan Xu · 1 shared paper, 2014 · strength 0.04
  21. Zheng Chen · 1 shared paper, 2014 · strength 0.04
  22. Xin Xie · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.